Lead Researcher in Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN

Postdoctoral training in NIDDK, National Institutes of Health, Bethesda, MD

PhD in Life Sciences, Gwangju Institute of Science & Technology, Gwangju, South Korea 

BS in Biochemical Engineering, Dongguk University, Seoul, South Korea

Drug discovery with target identification and validation is the process of finding new potential medications to treat disease. It involves a broad spectrum of scientific disciplines, including chemistry, biology, and pharmacology. Dr. Jung’s lab is professionally conducting translational research to treat catastrophic diseases such as pain, neurodegenerative disease, cancer, and infectious disease through various drug development programs.

Dr. Jung’s lab focuses on 1) Designing, synthesizing, and developing bioavailable small molecules. 2) Targeted protein degradation (TPD) as robust and innovative medications for reprogramming disease-related protein expression levels. 3) Investigate the drug combinations-induced epigenetic changes toward understanding protein expressions to develop multivalent epigenetic modifiers by the merged key pharmacophores of epigenetic drugs.

Lastly, we are actively pursuing interdisciplinary collaborations, which are the process of combining different perspectives, methods, and expertise from various disciplines to solve complex scientific problems.